TAKEDA PHARMACEUTICAL : Form 6-K

Document

FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of May 2024

Commission File Number: 001-38757

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(Translation of registrant's name into English)

1-1, Nihonbashi-Honcho 2-Chome

Chuo-ku, Tokyo 103-8668

Japan

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Information furnished on this form:

EXHIBIT

Exhibit Number
1	(Correction) Partial Correction of the Summary of Financial Statementsfor the Fiscal Year Ended March 31, 2024 (IFRS, Consolidated)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

TAKEDA PHARMACEUTICAL COMPANY LIMITED
Date: May 21, 2024	By:	/s/ Norimasa Takeda
Norimasa Takeda Chief Accounting Officer and Corporate Controller

Takeda Information

(Correction) Partial Correction of the Summary of Financial Statements
for the Fiscal Year Ended March 31, 2024 (IFRS, Consolidated)

OSAKA, Japan, May 21, 2024 - Takeda (TSE:4502/NYSE:TAK) today filed with the Tokyo Stock Exchange some corrections to the consolidated financial statements (IFRS) for the fiscal year ended March 31, 2024, which was filed on May 9, 2024. Corrections are highlighted as below. There are no corrections in the "Reported" and "Core" final financial results for the fiscal year ended March 31, 2024 and XBRL data that were submitted on the same date.

1.Corrections

[Financial Appendix]

FY2023 Reconciliation from Reported to Core (page A-7)

FY2023 Q4 (Jan-Mar) Reconciliation from Reported to Core (page A-8)

2.Reasons for Corrections

In the reconciliation tables from Reported to Core for the full year FY2023 and Q4 FY2023 in the Financial Appendix, adjustment amounts for "Income tax (expenses) benefit" and "Net profit attributable to owners of the Company" were incorrectly presented in the column titled, "Others". There are no corrections in the "Reported" and "Core" financial results.

###